Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CYCLON

Financiado

Cerrado

Novel multifunctional cyclodextrin based nanocarriers for drug encapsulation and...

Novel multifunctional cyclodextrin based nanocarriers for drug encapsulation and delivery as a strategy to overcome current therapeutic drawbacks There is a high demand for the development of new drug delivery strategies to combat major diseases in our society, particularly cancer. Current treatments are based on high efficacy drugs, however their non-selective uptake by bo... ver más

30/09/2013

"NCSR ""D"""

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

NATIONAL CENTER FOR SCIENTIFIC RESEARCH DEMOK... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-09-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

"NCSR ""D"""

0.00€ | Lider

University of Iceland

N.D. | Participante

UAL

N.D. | Participante

UCLM

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IPT-090000-2010-001 POLYSFERA: Nanocapsulas poliméricas para liberación controla... 369K€ Cerrado

NANOTHERAPY A Novel Nanocontainer drug carrier for targeted treatment of... 150K€ Cerrado

SAF2013-44848-R POLIMEROS TERAPEUTICOS COMO AGENTES SIMPLES Y EN COMBINACION... 218K€ Cerrado

CYCLON HIT NANOCARRIERS FOR THE DELIVERY OF ANTIMICROBIAL AGENTS TO FIG... 4M€ Cerrado

CTQ2010-15848 MANIPULACION DE LA TOPOLOGIA Y FUNCIONALIDAD DE LAS CICLODEX... 100K€ Cerrado

RTI2018-101309-B-C21 SINTESIS Y CARACTERIZACION DE NANOGHOSTS COMO SISTEMAS NOVED... 154K€ Cerrado

Líder del proyecto

NATIONAL CENTER FOR SCIENTIFIC RESEARCH DEMOK... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto There is a high demand for the development of new drug delivery strategies to combat major diseases in our society, particularly cancer. Current treatments are based on high efficacy drugs, however their non-selective uptake by both normal and tumor cells as well as the development of multidrug resistance (MDR), constitute major hurdles. Resistance is also associated with the use of nucleoside analogues as anticancer drugs in vivo. Photodynamic therapy (PDT), aims at selectively killing neoplastic lesions by the combined action of a photosensitizer and visible light. Passive targeting, involving enhanced permeability and retention effect, allows the accumulation of drugs on tumor sites, and concomitant active targeting with suitable functionalities, constitute properties currently associated with polymeric delivery systems. Cyclodextrins (CDs) are biocompatible and biodegradable oligosaccharide nanocages, known to improve the solubility, stability and bioavailability of drugs. Scattered literature reports incidents that CDs may constitute potential means to overcome certain forms of MDR, or to effectively deliver photosensitizing anticancer drugs preserving their photodynamic properties. This network, highly specialized in CD chemistry, photochemistry, in vitro drug evaluation and in vivo applications, proposes to synthesize diverse families of new CD derivatives to build a platform of CD-based drug delivery nanosystems with a variety of architectures. These new generation nanocarriers, encompassing many cavities in a nm-sized vehicle, will possess high drug loading capacity, improved permeability and retention effect, enhanced targeting and complete biocompatibility. Their mode of action will be assessed in vitro and in vivo. These goals will be achieved via a strong training program of ESRs and ERs in a highly collaborating, multidisciplinary and application oriented program, with full participation of an SME partner, a leader in CD applications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores